Aripiprazole oral

Amber

Brand Name(s):Abilify

Indication:Antipsychotic – patients NOT on the SMI register

Rationale:1,2

Considered:Oct-19

Review Date:Oct-24

Comments:
RDaSH protocol for managing behavioural & psychological symptoms in patients with dementia can be found at: http://medicinesmanagement.doncasterccg.nhs.uk/guidelines/central-nervous-system/
Feb 2015

…………………………
Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken
NICE CG178
Psychosis and schizophrenia in adults: treatment and management
Full details at:https://www.nice.org.uk/guidance/cg178/resources/guidance-psychosis-and-schizophrenia-in-adults-treatment-and-management-pdf
Feb 2014

…………………………
NICE CG 185 Assessment & Management of bipolar disorder
further details at: http://www.nice.org.uk/guidance/cg185/resources/guidance-bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care-pdf
September 2014
…………………………
Psychosis and schizophrenia in children and young people
National Clinical Guideline Number CG155
January 2013
Guidance available at: http://www.nice.org.uk/nicemedia/live/14021/62392/62392.pdf
…………………………

1.1 Aripiprazole is recommended as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone.

1.2 People aged 15 to 17 years currently receiving aripiprazole for the treatment of schizophrenia who do not meet the criteria specified in 1.1 should have the option to continue treatment until it is considered appropriate to stop. This decision should be made jointly by the clinician and the person with schizophrenia, and if appropriate, their parents or carers.

NICE TA 213
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years January 2011

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009